I-Mab, WuXi enter into long-term strategic manufacturing partnership
I, April 24 -- Mab Biopharma (I-Mab), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, and WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, jointly announced that the two companies have entered into a long-term strategic partnership on biologics process development, clinical and commercial manufacturing of I-Mab's highly innovative pipelines.
Under the terms of the partnership, I-Mab will leverage WuXi Bio's expertise and capabilities for CMC development of at least five programs and commercial manufacturing of at least one program for its proprietary monoclonal...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.